Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages

Abstract Background Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for GBM. This s...

Full description

Saved in:
Bibliographic Details
Main Authors: Rongrong Zhao, Ziwen Pan, Jiawei Qiu, Boyan Li, Yanhua Qi, Zijie Gao, Wei Qiu, Weijie Tang, Xiaofan Guo, Lin Deng, Gang Li, Hao Xue
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Cancer Communications
Subjects:
Online Access:https://doi.org/10.1002/cac2.70016
Tags: Add Tag
No Tags, Be the first to tag this record!